This guide is currently available in English. A Spanish version is in progress.
Sourcing Exosomes in Utah
Licensed Utah practices order Kimera exosome material from ExaVeyra for topical aesthetic use, shipped frozen from Florida with a Certificate of Analysis and lot traceability on every vial. Utah buyers need their own professional license and NPI; the Class C pharmacy license for wholesale distribution is the supplier’s obligation, not the purchaser’s.
Utah is one of the few states with a stem cell statute, and since 6 May 2026 it is the only one we know of that speaks to suppliers directly: a person may supply cells, tissues, or cellular or tissue-based products for stem cell therapy only after the provider confirms in writing that patients will receive the statutory notice. It is worth knowing exactly what that law covers, and what it does not.
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to Utah? | Yes. Shipped frozen from Florida, as we do to all 50 states |
| Cold-chain shipping from Florida | Overnight shipping; arrival can take 1 to 3 business days |
| State regenerative-medicine statute | SB 199 (2024) |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | Yes |
| Who holds the licensure to ship into the state | The pharmacy partner and the tissue bank that ship, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material; compounded preparations available through the 503A pharmacy partner |
| Last reviewed | 16 October 2026 |
Ordering from Utah
ExaVeyra ships to licensed practices in all 50 states, Utah included. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner holds nonresident pharmacy licenses in 33 jurisdictions, including Puerto Rico, and exosome material ships from a registered tissue bank licensed to ship to all 50 states and Puerto Rico. Your practice orders against its own professional license and NPI and needs no wholesale permit to purchase.
What your practice provides
- An active Utah professional license in good standing, verifiable through the Division of Professional Licensing license verification system.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed professional-use acknowledgment on file for exosome material.
- A Utah sales and use tax exemption certificate from the Utah State Tax Commission if the practice is purchasing for resale rather than for use in its own operations.
How the state permits wholesale distribution
Utah folds wholesale licensing into its pharmacy facility classes rather than running a standalone wholesaler regime. A Class C pharmacy is one that engages in the manufacture, production, wholesale, or distribution of drugs or devices, with wholesaler, distributor, manufacturer, and virtual subtypes, and a separate license for each location. Two things stand out: the Class C class covers devices as well as prescription drugs, which is broader than most states’ prescription-drug-only regimes, and every pharmacy class answers to a single agency, the Division of Professional Licensing within the Department of Commerce. The license sits with the distributor, not with the purchasing practice.
Utah Code 58-17b-102, 58-17b-302; Utah Admin. Code R156-17b · Utah Division of Professional Licensing (DOPL), Board of Pharmacy
Utah regenerative-medicine law
Utah enacted SB 199, codified at Utah Code 58-1-512, effective 1 May 2024.
Health care providers whose scope of practice includes stem cell therapy, as "health care provider" is defined in Utah Code 78B-3-403. The statute authorizes nothing: it conditions an unapproved stem cell therapy on a prominently displayed written notice, a signed consent form, and the same notice in advertising, and makes a violation unprofessional conduct. The 2026 amendment, SB 55, added subsection (2)(b), which is addressed to suppliers: a person may supply human cells, tissues, or cellular or tissue-based products to a provider for stem cell therapy only after the provider gives written confirmation that each patient whose therapy uses the material will receive the statutory notice. Providers holding an FDA investigational new drug approval and providers working for institutions accredited by bodies such as FACT or AABB are exempt.
- Written patient notice before any stem cell therapy not approved by the FDA
- Notice displayed in the office entrance, in at least forty point type
- Signed consent covering FDA approval status, anticipated results, alternatives, and risks
- The notice repeated in any advertisement for the therapy
- Since 6 May 2026, written confirmation to the supplier before cells or tissues are provided
- Exemptions for IND holders and providers at accredited transplant institutions
“"Stem cell therapy" means a treatment involving the use of afterbirth placental perinatal stem cells or human cells, tissues, or cellular or tissue-based products.”
How this applies to exosomes
Utah Code 58-1-512 is written around cells and tissues: its defined term covers afterbirth placental perinatal stem cells and human cells, tissues, or cellular or tissue-based products as defined in 21 C.F.R. 1271.3, and nothing in it names exosomes or extracellular vesicles. Exosomes are acellular extracellular vesicles rather than stem cells, so the statute does not reach them either to permit or to restrict, and there is no Utah definition that does. The 2026 supplier confirmation clause is still worth knowing about, because practices that also administer cellular products will encounter it from their tissue suppliers. Exosome products in Utah remain governed by federal law, under which no exosome product has been approved by the FDA for administration to humans. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with full COA and lot documentation.
Who can handle product in a Utah practice
Because qualifying APRNs hold independent authority in Utah, there are two workable structures rather than one: an APRN-led practice evaluating and ordering within APRN scope, and a physician-led practice delegating conventionally, with a medical director still needed where a procedure falls outside APRN scope or a payer requires one. Every profession on this page is licensed by one agency, the Division of Professional Licensing within the Department of Commerce, so verification runs through a single portal. One Utah-specific item belongs in onboarding: under 58-1-512 as amended in 2026, a practice performing stem cell therapy gives its supplier written confirmation that patients will receive the statutory notice before cellular material is supplied.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians licensed by the Division of Professional Licensing under the Utah Medical Practice Act perform medical acts within their scope and are the source of delegation to staff without independent authority. Utah also codifies cosmetic medical procedure definitions in statute, separating ablative procedures from nonablative ones, so who may perform an energy-based treatment is a matter of statute and rule rather than guidance alone. |
| NP / APRN | Utah is a full practice authority state. The practice of advanced practice registered nursing under the Nurse Practice Act includes diagnosis, treatment, and the prescription of drugs and devices without a physician protocol. The consultation and referral plan survives only for Schedule II prescribing, and 58-31b-803 lets an APRN prescribe even those independently after the lesser of two years of licensure or 2,000 hours of APRN practice, with Controlled Substance Database checks. |
| PA | Physician assistants practice under the Utah Physician Assistant Act, which was modernized to a collaboration model: Utah Code 58-70a-501 lets a PA provide medical services within the PA’s skills and competence, with the degree of collaboration determined at the practice level, subject to the experience requirements of 58-70a-307. |
| RN | Registered nurses perform delegated treatments within their license and under an order from a provider with authority to issue one. An RN does not evaluate the patient or select the treatment plan. |
Good faith examination
Utah expects a patient evaluation by a provider with authority to conduct it, and an order, before a delegated treatment is administered. Where an advanced practice registered nurse holds independent authority, that provider can be the APRN. For cosmetic medical procedures the Medical Practice Act and DOPL rules set supervision expectations, so confirm current requirements with the Division before building delegation protocols.
Ownership and clinic licensing
Utah sits at the permissive end of the corporate practice spectrum, and unusually, it says so in statute. Utah Code 58-67-802 lets a licensed physician practice as a business proprietor, as an employee of another person, or through a partnership, professional corporation, LLC, or business corporation, provided the practice of medicine itself is conducted only by Utah-licensed physicians. Management arrangements and non-physician investment are therefore workable here in ways they are not in strict states, though the structure still deserves review by Utah counsel.
Cold chain into Utah
Shipments leave Florida frozen under validated temperature monitoring. A package in transit over a weekend waits in the carrier network, so practices in Utah order around weekend and holiday closures.
| Metro | County | Notes |
|---|---|---|
| Salt Lake City | Salt Lake | Largest Utah market, with aesthetic and longevity coverage along the Wasatch Front. |
| Provo | Utah | Fast-growing Utah County market anchored by the university corridor. |
| Park City | Summit | Resort market with orthopedic and sports medicine concentration. |
| Lehi | Utah | Silicon Slopes corridor with a growing concierge and wellness segment. |
| Ogden | Weber | Northern Wasatch Front market served alongside Salt Lake City. |
| St. George | Washington | Southwest Utah hub with a retiree-driven aesthetic base. |
- Utah orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
- The lot-specific Certificate of Analysis is provided on request for every lot; the manufacturer’s handling instructions accompany each order, so store to the labeled conditions on arrival.
Wholesale exosome supply by city in Utah
Each city page covers local receiving conditions, delivery disruptions and business license rules for Utah practices in that area.
Practice types we supply in Utah
Utah licensing and verification
Utah Division of Professional Licensing, Physicians and Surgeons
All Utah professional licensing sits within DOPL, so verification runs through a single agency.
Utah Division of Professional Licensing, Nursing
Utah Division of Professional Licensing, Pharmacy
Issues the Class C pharmacy license that covers wholesalers and distributors.
Utah State Tax Commission
Sales and use tax registration and exemption certificates.
Utah sourcing questions
- Does Utah have a stem cell law?
- Yes, a disclosure law. Utah Code 58-1-512, enacted by SB 199 in 2024 and amended by SB 55 in 2026, conditions any stem cell therapy not approved by the FDA on a prominently displayed written notice, a signed consent form, and the same notice in advertising. It authorizes nothing and names no conditions; a violation is unprofessional conduct. Providers with an FDA investigational new drug approval and providers at accredited transplant institutions are exempt.
- What did Utah’s 2026 amendment change for suppliers?
- SB 55, effective 6 May 2026, added a clause addressed to suppliers: a person may supply human cells, tissues, or cellular or tissue-based products to a provider for stem cell therapy only after the provider gives written confirmation that each patient whose therapy uses the material will receive the statutory notice. No other state statute we track speaks to the supply step this way, which is why practices that administer cellular products will see confirmation paperwork from their tissue suppliers.
- Does Utah’s stem cell disclosure law cover exosomes?
- The statute is written around cells and tissues: afterbirth placental perinatal stem cells and HCT/Ps as defined in 21 C.F.R. 1271.3. It does not name exosomes or extracellular vesicles, and exosomes are acellular. Exosome products are governed federally, and no exosome product is FDA-approved for administration to humans.
- Are exosomes FDA approved?
- No exosome product has been approved by the FDA for administration to humans, in Utah or anywhere else, and the FDA has issued a public safety notification saying exactly that. ExaVeyra supplies Kimera exosome material for topical aesthetic use by licensed practitioners, with a Certificate of Analysis and lot documentation on every vial.
- Can a nurse practitioner run a practice in Utah without a physician?
- Utah is a full practice authority state. Advanced practice registered nursing includes diagnosis, treatment, and prescribing without a physician protocol; a consultation and referral plan survives only for Schedule II prescribing, and even that requirement falls away after the lesser of two years of licensure or 2,000 hours of APRN practice. A medical director is still needed where a procedure falls outside APRN scope or a payer requires one.
- Does my Utah clinic need a Class C pharmacy license to buy exosomes?
- No. The Class C license under Utah Code 58-17b-302 is held by the facility that manufactures, wholesales, or distributes, not by the practice buying. Your practice orders against its own professional license and NPI. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner for compounded preparations, and a registered tissue bank licensed to ship to all 50 states and Puerto Rico for exosome material.
- How long does cold-chain shipping take to Utah?
- Ships from Florida by overnight shipping, and arrival can take one to three business days. All exosome shipments travel cold-chain with validated temperature monitoring. A shipment in transit over a weekend waits in the carrier network, so a practice that will be closed orders around the closure.
Sources
Last reviewed 16 October 2026 by ExaVeyra Sciences editorial team. Every claim above links to a primary source.
- Utah SB 55 (2026), Placental Tissue Amendments, enrolled text (accessed 16 October 2026)
- Utah Code 58-1-512, stem cell disclosure (accessed 16 October 2026)
- Utah Code 58-67-802, form of practice (accessed 16 October 2026)
- Utah DOPL, pharmacy licensing (accessed 16 October 2026)
- Utah DOPL, nursing licensing (accessed 16 October 2026)
- Utah State Tax Commission (accessed 16 October 2026)
- FDA Public Safety Notification on Exosome Products (accessed 16 October 2026)
Scientific literature
Peer-reviewed references, each with its study design and, for human studies, the number of participants, so a reader can judge the weight of a citation without opening it. None is a claim about any product.
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles, 2024. doi:10.1002/jev2.12404 PMID:38326288Clinical guidelinesupports: The current international reporting standard for extracellular vesicle characterization, the framework behind the identity and purity parameters a Utah practice should expect on an exosome Certificate of Analysis.
- Witwer KW, Van Balkom BWM, Bruno S, et al. Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. Journal of Extracellular Vesicles, 2019. doi:10.1080/20013078.2019.1609206 PMID:31069028Consensus statementsupports: The ISEV position paper on what an MSC-derived small EV preparation must document, which supports this page’s point that supplier documentation, not any state statute, is where exosome quality is established.
- Kou M, Huang L, Yang J, et al. Mesenchymal stem cell-derived extracellular vesicles for immunomodulation and regeneration: a next generation therapeutic tool?. Cell Death and Disease, 2022. doi:10.1038/s41419-022-05034-x PMID:35787632Narrative reviewsupports: Reviews the preclinical literature on MSC-derived EVs, including perinatal sources like the placental tissue named in Utah’s statute, and distinguishes acellular vesicles from the stem cells themselves.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and are not tissue products as defined by FDA guidelines.